BMO Capital Markets says Gilead Sciences is a "best-in-class" therapy franchise that could soon see multiple expansion. "Simply put, Gilead has the best cell therapy manufacturing capabilities vs. competition from Novartis and Bristol. When comparing the three, Gilead is not supply constrained, able to meet increasing demand for Yescarta and Tecartus," BMO said in a Tuesday note.
Analyst Evan David Seigerman said that, in addition to Gilead's strong therapy franchise, its improving solid tumor oncology business and durable-growth anchored by its HIV/virology division could lead to strong growth. "Our Outperform rating is supported by our analysis of the current base business and positivity on the oncology franchise as the company's next leg of growth ," said Seigerman.